Table 4.
Factors Independently Associated with Thrombocytopenia in Hospitalized Patients with Linezolid Therapy
| Variable | Estimate | s.e. | Wald’s χ2 | OR (95% CI) | P-value |
|---|---|---|---|---|---|
| Renal insufficiency | 0.085 | 0.301 | 0.026 | 1.712 (0.531–2.675) | 0.931 |
| CRRT | 0.283 | 0.361 | 0.797 | 1.486 (0.812–2.397) | 0.452 |
| Duration of linezolid therapy≥10d | 0.956 | 0.001 | 21.58 | 1.169 (0.857–1.421) | 0.001 |
| The difference of MPV | −0.006 | 0.201 | 15.632 | 0.459 (0.372–0.857) | 0.001 |
| The difference of PLCR | 0.135 | 0.027 | 13.622 | 1.156 (1.078–1.359) | 0.001 |
| Baseline PLT counts, ×109/L | −0.005 | 0.001 | 7.855 | 0.995 (0.991–0.998) | 0.006 |
| Baseline RBC, ×1012/L | −0.539 | 0.317 | 7.8 | 0.578 (0.459–0.916) | 0.005 |
| Caspofungin | 0.975 | 0.318 | 5.94 | 2.521 (1.056–6.238) | 0.025 |
| CREA, μmol/L | 0.261 | 0.006 | 0.009 | 1.311 (0.998–1.561) | 0.939 |
| Parecoxib | 0.753 | 0.268 | 9.5 | 1.346 (0.951–1.528) | 0.007 |
| ALT, U/L | 0.001 | 0.005 | 0.312 | 1.000 (0.999–1.001) | 0.683 |
Note: Bold part represents: a higher risk of linezolid related thrombocytopenia in hospitalized patients (P< 0.1).
Abbreviations: CRRT, continuous renal replacement therapy; the difference of MPV, the difference between mean platelet volume of starting and stopping linezolid; the difference of PLCR, the difference between platelet large cell ratio of starting and stopping linezolid; PLT, platelet; RBC, red blood cells; CREA, creatinine; ALT, alanine transaminase.